These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 6985187)

  • 21. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deferral of initial therapy for advanced indolent lymphomas.
    Portlock CS
    Cancer Treat Rep; 1982 Mar; 66(3):417-9. PubMed ID: 7037178
    [No Abstract]   [Full Text] [Related]  

  • 23. Combinations of methotrexate (COP or CHOP) in the treatment of previously untreated and treated lymphomas.
    Gomez GA; Stutzman L; Moayeri H; Shimaoka K; Plager J; Han T; Naeher C; Henderson E
    Cancer Treat Rep; 1982 Jan; 66(1):43-7. PubMed ID: 6975659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chemotherapy of non-Hodgkin lymphoma with poor prognosis].
    Rupniewska ZM; Kurowska M
    Pol Arch Med Wewn; 1980 Aug; 64(2):167-79. PubMed ID: 6159608
    [No Abstract]   [Full Text] [Related]  

  • 25. Results of combination chemotherapy of non-Hodgkin's lymphoma.
    Schein PS; Chabner BA; Canellos GP; Young RD; Berard C; DeVita VT
    Br J Cancer Suppl; 1975 Mar; 2():465-73. PubMed ID: 1101932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiation as salvage therapy for patients with Hodgkin's disease relapsing after MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy.
    Diehl LF; Perry DJ; Terebelo H; Baldwin PE; Hurwitz M; Kimball DB; Dorn RV
    Cancer Treat Rep; 1983 Sep; 67(9):827-9. PubMed ID: 6883360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
    Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
    Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs.
    Northrup NC; Gieger TL; Kosarek CE; Saba CF; LeRoy BE; Wall TM; Hume KR; Childress MO; Keys DA
    Vet Comp Oncol; 2009 Mar; 7(1):38-44. PubMed ID: 19222829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MOPP, ABVD, or both to treat Hodgkin's disease.
    Martino R; Nomdedeu J; Brunet S
    N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680766
    [No Abstract]   [Full Text] [Related]  

  • 30. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
    Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T
    Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hodgkin's disease; tracheoesophageal fistula during MOPP chemotherapy.
    Weiner MJ; Sicular A; Blaugrund SM; Sattler SM
    N Y State J Med; 1981 Sep; 81(10):1509-11. PubMed ID: 6944619
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of two combination chemotherapies in previously untreated non Hodgkin's lymphoma.
    Somoza N; Pavlovsky S; Suárez A; Morgenfeld M; Besuschio SC; Bezares R; Quiroga Micheo E; Lein JM; De María H
    Medicina (B Aires); 1981; 41 Suppl():35-43. PubMed ID: 7345350
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
    Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy.
    Longo DL; Glatstein E; Duffey PL; Ihde DC; Hubbard SM; Fisher RI; Jaffe ES; Gilliom M; Young RC; DeVita VT
    J Clin Oncol; 1989 Sep; 7(9):1295-302. PubMed ID: 2788716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy for advanced Hodgkin's disease: conclusions from the Southeastern Cancer Study Group.
    Gams RA; Durant JR; Bartolucci AA
    Cancer Treat Rep; 1982 Apr; 66(4):899-905. PubMed ID: 7042089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
    Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
    Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of combined-modality therapy in the curative management of advanced-stage "favorable" non-Hodgkin's lymphomas.
    Kinsella TJ
    Cancer Treat Rep; 1982 Mar; 66(3):421-5. PubMed ID: 7037179
    [No Abstract]   [Full Text] [Related]  

  • 40. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
    Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
    J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.